RVT 301

Drug Profile

RVT 301

Alternative Names: RVT-301

Latest Information Update: 13 Sep 2016

Price : $50

At a glance

  • Originator Roivant Sciences
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glycogen storage disease type I; Glycogen storage disease type II

Most Recent Events

  • 09 Sep 2016 Phase-I clinical trials in Glycogen storage disease type II before September 2016 (Roivant Sciences pipeline, September 2016)
  • 09 Sep 2016 Phase-I clinical trials in Glycogen storage disease type I before September 2016 (Roivant Sciences pipeline, September 2016)
  • 09 Sep 2016 Roivant Sciences and Duke University agree to co-develop RVT 301 for glycogen storage disorders and orphan paediatric disorders (Roivant Sciences website, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top